{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:12:12Z","timestamp":1793081532218,"version":"4.5.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K01DK114164"],"award-info":[{"award-number":["K01DK114164"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K01DK103678"],"award-info":[{"award-number":["K01DK103678"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK118215"],"award-info":[{"award-number":["R03DK118215"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001296","name":"PKD Foundation","doi-asserted-by":"publisher","award":["216G18a"],"award-info":[{"award-number":["216G18a"]}],"id":[{"id":"10.13039\/100001296","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>\n                    Autosomal dominant polycystic kidney disease is characterized by progressive development and enlargement of kidney cysts, leading to ESKD. Because the kidneys are under high metabolic demand, it is not surprising that mounting evidence suggests that a metabolic defect exists in\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    and animal models of autosomal dominant polycystic kidney disease, which likely contributes to cystic epithelial proliferation and subsequent cyst growth. Alterations include defective glucose metabolism (reprogramming to favor aerobic glycolysis), dysregulated lipid and amino acid metabolism, impaired autophagy, and mitochondrial dysfunction. Limited evidence supports that cellular kidney metabolism is also dysregulated in humans with autosomal dominant polycystic kidney disease. There are notable overlapping features and pathways among metabolism, obesity, and\/or autosomal dominant polycystic kidney disease. Both dietary and pharmacologic-based strategies targeting metabolic abnormalities are being considered as therapies to slow autosomal dominant polycystic kidney disease progression and are attractive, particularly given the slowly progressive nature of the disease. Dietary strategies include daily caloric restriction, intermittent fasting, time-restricted feeding, a ketogenic diet, and 2-deoxy-glucose as well as alterations to nutrient availability. Pharmacologic-based strategies include AMP-activated kinase activators, sodium glucose cotransporter-2 inhibitors, niacinamide, and thiazolidenediones. The results from initial clinical trials targeting metabolism are upcoming and anxiously awaited within the scientific and polycystic kidney disease communities. There continues to be a need for additional mechanistic studies to better understand the role of dysregulated metabolism in autosomal dominant polycystic kidney disease and for subsequent translation to clinical trials. Beyond single-intervention trials focused on metabolic reprograming in autosomal dominant polycystic kidney disease, great potential also exists by combining metabolic-focused therapeutic approaches with compounds targeting other signaling cascades altered in autosomal dominant polycystic kidney disease, such as tolvaptan.\n                  <\/jats:p>","DOI":"10.2215\/cjn.13291019","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T15:25:15Z","timestamp":1582298715000},"page":"577-584","source":"Crossref","is-referenced-by-count":123,"title":["Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03342742","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02903511","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03764605","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03273413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02558595","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02697617","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-3256","authenticated-orcid":false,"given":"Kristen L.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41581-019-0183-y","article-title":"The pathobiology of polycystic kidney disease from a metabolic viewpoint","volume":"15","author":"Menezes","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl 1","key":"B4-20230813","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ckj\/sfy089","article-title":"Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease","volume":"11","author":"Weimbs","year":"2018","journal-title":"Clin Kidney J"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","article-title":"Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease","volume":"11","author":"Riwanto","year":"2016","journal-title":"PLoS One"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"5","author":"Menezes","year":"2016","journal-title":"EBioMedicine"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-Deoxy-d-glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00109-015-1337-4","article-title":"Glucose promotes secretion-dependent renal cyst growth","volume":"94","author":"Kraus","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"F79","DOI":"10.1152\/ajprenal.00652.2014","article-title":"Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage","volume":"309","author":"Sas","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"e1003053","DOI":"10.1371\/journal.pgen.1003053","article-title":"Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4\u03b1 as a disease modifier","volume":"8","author":"Menezes","year":"2012","journal-title":"PLoS Genet"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","article-title":"PPAR\u03b1 agonist fenofibrate enhances fatty acid \u03b2-oxidation and attenuates polycystic kidney and liver disease in mice","volume":"314","author":"Lakhia","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/ndt\/gfx349","article-title":"Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease","volume":"33","author":"Soomro","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-018-03036-y","article-title":"Lkb1 deficiency confers glutamine dependency in polycystic kidney disease","volume":"9","author":"Flowers","year":"2018","journal-title":"Nat Commun"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"F1855","DOI":"10.1152\/ajprenal.00025.2018","article-title":"Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis","volume":"315","author":"Trott","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.3390\/nu11010042","article-title":"Effect of trehalose supplementation on autophagy and cystogenesis in a mouse model of polycystic kidney disease","volume":"11","author":"Chou","year":"2018","journal-title":"Nutrients"},{"key":"B18-20230813","first-page":"158","article-title":"Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model","volume":"26","author":"Zhu","year":"2017","journal-title":"Hum Mol Genet"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"F1235","DOI":"10.1152\/ajprenal.00348.2010","article-title":"Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) and autophagy in polycystic kidney disease (PKD)","volume":"300","author":"Belibi","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41598-018-20856-6","article-title":"A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1091\/mbc.e16-08-0597","article-title":"The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function","volume":"28","author":"Padovano","year":"2017","journal-title":"Mol Biol Cell"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-019-1249-6","article-title":"Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course","volume":"20","author":"Kim","year":"2019","journal-title":"BMC Nephrol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1194\/jlr.P042176","article-title":"Bioactive lipid mediators in polycystic kidney disease","volume":"55","author":"Klawitter","year":"2014","journal-title":"J Lipid Res"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2215\/CJN.02560317","article-title":"Metabolomic alterations associated with cause of CKD","volume":"12","author":"Grams","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/ndt\/gfu044","article-title":"Metabolic abnormalities in autosomal dominant polycystic kidney disease","volume":"30","author":"Mao","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","article-title":"The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"Reed","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcjd.2016.03.001","article-title":"The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis","volume":"40","author":"Cheungpasitporn","year":"2016","journal-title":"Can J Diabetes"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.ki.5002586","article-title":"Association between obesity and kidney disease: A systematic review and meta-analysis","volume":"73","author":"Wang","year":"2008","journal-title":"Kidney Int"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2215\/CJN.02250409","article-title":"Weight loss interventions in chronic kidney disease: A systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1158\/1940-6207.CAPR-08-0022","article-title":"Dietary energy balance modulates signaling through the Akt\/mammalian target of rapamycin pathways in multiple epithelial tissues","volume":"1","author":"Moore","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","article-title":"mTOR Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer","volume":"13","author":"Dann","year":"2007","journal-title":"Trends Mol Med"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00011.2008","article-title":"AMPK in health and disease","volume":"89","author":"Steinberg","year":"2009","journal-title":"Physiol Rev"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cell.2015.02.020","article-title":"Promoting health and longevity through diet: From model organisms to humans","volume":"161","author":"Fontana","year":"2015","journal-title":"Cell"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/apha.12120","article-title":"Caloric restriction ameliorates kidney ischaemia\/reperfusion injury through PGC-1\u03b1-eNOS pathway and enhanced autophagy","volume":"208","author":"Lempi\u00e4inen","year":"2013","journal-title":"Acta Physiol (Oxf)"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cmet.2013.12.008","article-title":"Fasting: Molecular mechanisms and clinical applications","volume":"19","author":"Longo","year":"2014","journal-title":"Cell Metab"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.1256682","article-title":"Time-restricted feeding attenuates age-related cardiac decline in Drosophila","volume":"347","author":"Gill","year":"2015","journal-title":"Science"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cmet.2014.11.001","article-title":"Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges","volume":"20","author":"Chaix","year":"2014","journal-title":"Cell Metab"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2012.04.019","article-title":"Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet","volume":"15","author":"Hatori","year":"2012","journal-title":"Cell Metab"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/gerona\/glv057","article-title":"A 2-year Randomized controlled trial of human caloric restriction: Feasibility and effects on predictors of health span and longevity","volume":"70","author":"Ravussin","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3945\/ajcn.2009.28380","article-title":"Short-term modified alternate-day fasting: A novel dietary strategy for weight loss and cardioprotection in obese adults","volume":"90","author":"Varady","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/oby.20909","article-title":"Meal timing during alternate day fasting: Impact on body weight and cardiovascular disease risk in obese adults","volume":"22","author":"Hoddy","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/ijo.2010.171","article-title":"The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: A randomized trial in young overweight women","volume":"35","author":"Harvie","year":"2011","journal-title":"Int J Obes"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"16647","DOI":"10.1073\/pnas.1413965111","article-title":"Meal frequency and timing in health and disease","volume":"111","author":"Mattson","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cmet.2015.09.005","article-title":"A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits","volume":"22","author":"Gill","year":"2015","journal-title":"Cell Metab"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1681\/ASN.V561355","article-title":"Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease","volume":"5","author":"Tomobe","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"B51-20230813","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1523-1755.2000.00835.x","article-title":"Modification of polycystic kidney disease and fatty acid status by soy protein diet","volume":"57","author":"Ogborn","year":"2000","journal-title":"Kidney Int"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"B54-20230813","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","article-title":"Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat","volume":"26","author":"Gile","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"B55-20230813","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B56-20230813","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B57-20230813","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"B58-20230813","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"B59-20230813","doi-asserted-by":"crossref","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"key":"B60-20230813","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"B61-20230813","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J Clin Invest"},{"key":"B62-20230813","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1152\/ajprenal.00090.2009","article-title":"PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line","volume":"297","author":"Nofziger","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B63-20230813","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/CS20100113","article-title":"Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats","volume":"119","author":"Dai","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"B64-20230813","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","article-title":"Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant","volume":"11","author":"Muto","year":"2002","journal-title":"Hum Mol Genet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13291019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:35Z","timestamp":1786369175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13291019"}},"subtitle":["Evidence and Therapeutic Potential"],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13291019","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}